Skip to content

Study · Non-randomized trial · 2017

4 results

Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.

Meier JJ, Schenker N, Kahle M, Schliess F, Kapitza C, Menge BA

Diabetes, obesity & metabolism31 May 2017Cited by 8 (Europe PMC)

PMID28407415 (opens in a new tab)DOI10.1111/dom.12968 (opens in a new tab)PepBankPUB-28407415
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In people with type 2 diabetes, adding lixisenatide after glargine increased first-phase insulin secretion (P < .001).

    In plain wordsIn people with diabetes, first-phase insulin secretion increased after lixisenatide was added to glargine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseFirst-phase insulin secretion after addition
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Measurements

    P value
    < 0.001
    first-phase insulin secretion after lixisenatide added to glargine

    Source sentences

    Summary
    First- and second-phase insulin secretion were not increased with glargine alone, but increased after addition of lixisenatide ( P  < .001).
    1 context sentence
    Summary · context
    A total of 28 people with type 2 diabetes (glycated haemoglobin 7.8% ± 0.5%) were treated with either lixisenatide or titrated insulin glargine, followed by their combined administration, each over 4 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In people with type 2 diabetes, adding lixisenatide after glargine increased second-phase insulin secretion (P < .001).

    In plain wordsIn people with diabetes, second-phase insulin secretion increased after lixisenatide was added to glargine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSecond-phase insulin secretion after addition
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Measurements

    P value
    < 0.001
    second-phase insulin secretion after lixisenatide added to glargine

    Source sentences

    Summary
    First- and second-phase insulin secretion were not increased with glargine alone, but increased after addition of lixisenatide ( P  < .001).
    1 context sentence
    Summary · context
    A total of 28 people with type 2 diabetes (glycated haemoglobin 7.8% ± 0.5%) were treated with either lixisenatide or titrated insulin glargine, followed by their combined administration, each over 4 weeks.
  3. 03HumanNon-randomized trialEfficacy outcome

    In people with type 2 diabetes, lixisenatide alone increased first-phase insulin secretion (P < .01).

    In plain wordsIn people with diabetes, first-phase insulin secretion increased from baseline with lixisenatide alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseFirst-phase insulin secretion with monotherapy
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Measurements

    P value
    < 0.01
    first-phase insulin secretion, lixisenatide alone

    Source sentences

    Summary
    Lixisenatide alone increased first- and second-phase insulin secretion ( P  < .01).
    1 context sentence
    Summary · context
    A total of 28 people with type 2 diabetes (glycated haemoglobin 7.8% ± 0.5%) were treated with either lixisenatide or titrated insulin glargine, followed by their combined administration, each over 4 weeks.
  4. 04HumanNon-randomized trialEfficacy outcome

    In people with type 2 diabetes, lixisenatide alone increased second-phase insulin secretion (P < .01).

    In plain wordsIn people with diabetes, second-phase insulin secretion increased from baseline with lixisenatide alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSecond-phase insulin secretion with monotherapy
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Measurements

    P value
    < 0.01
    second-phase insulin secretion, lixisenatide alone

    Source sentences

    Summary
    Lixisenatide alone increased first- and second-phase insulin secretion ( P  < .01).
    1 context sentence
    Summary · context
    A total of 28 people with type 2 diabetes (glycated haemoglobin 7.8% ± 0.5%) were treated with either lixisenatide or titrated insulin glargine, followed by their combined administration, each over 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.